JP3350722B2 - Antithrombotic mesh filter for body fluid treatment circuit and method of manufacturing the same - Google Patents
Antithrombotic mesh filter for body fluid treatment circuit and method of manufacturing the sameInfo
- Publication number
- JP3350722B2 JP3350722B2 JP09261696A JP9261696A JP3350722B2 JP 3350722 B2 JP3350722 B2 JP 3350722B2 JP 09261696 A JP09261696 A JP 09261696A JP 9261696 A JP9261696 A JP 9261696A JP 3350722 B2 JP3350722 B2 JP 3350722B2
- Authority
- JP
- Japan
- Prior art keywords
- mesh filter
- body fluid
- antithrombotic
- mesh
- corona discharge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims description 39
- 210000001124 body fluid Anatomy 0.000 title claims description 32
- 239000010839 body fluid Substances 0.000 title claims description 28
- 230000002785 anti-thrombosis Effects 0.000 title claims description 24
- 239000003146 anticoagulant agent Substances 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 238000003851 corona treatment Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- 208000028659 discharge Diseases 0.000 claims description 13
- 239000000560 biocompatible material Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 229920000728 polyester Polymers 0.000 claims description 12
- -1 polyethylene terephthalate Polymers 0.000 claims description 11
- 239000004952 Polyamide Substances 0.000 claims description 6
- 229920002647 polyamide Polymers 0.000 claims description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 6
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 208000007536 Thrombosis Diseases 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940087051 fragmin Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003913 materials processing Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Materials For Medical Uses (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
Description
【0001】[0001]
【発明の属する技術分野】本発明は、体液処理回路用抗
血栓メッシュフィルター及びその処理方法に関するもの
で、更に詳しくは血液透析・血漿交換等の体液処理回路
に用いられるメッシュフィルターに血栓が付着するのを
極力防止し得る体液処理回路用抗血栓メッシュフィルタ
ー及びその処理方法に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antithrombotic mesh filter for a body fluid treatment circuit and a method for treating the same, and more particularly, a thrombus adheres to a mesh filter used in a body fluid treatment circuit such as hemodialysis and plasma exchange. The present invention relates to an antithrombotic mesh filter for a body fluid treatment circuit and a method for treating the same, which can prevent the occurrence of the thrombus as much as possible.
【0002】[0002]
【従来の技術】人工臓器透析法は、体内の血液を体外に
取り出し、血液循環回路を通した後、再び体内に戻すこ
とにより血液の透析を行う方法であるが、この血液循環
回路中には、ドリップチャンバーを有し、このドリップ
チャンバーにはメッシュフィルターが用いられている。
図1は、ドリップチャンバーの略図であり、このドリッ
プチャンバー1の下部にメッシュフィルター支持体7を
覆ってメッシュフィルター2が設けられている。血液は
血液導入口4から入り、メッシュフィルター2を通過し
血液導出口5から出る。2. Description of the Related Art Artificial organ dialysis is a method in which blood in the body is taken out of the body, passed through a blood circulation circuit, and then returned to the body to perform blood dialysis. , A drip chamber, and a mesh filter is used in the drip chamber.
FIG. 1 is a schematic view of a drip chamber, and a mesh filter 2 is provided below the drip chamber 1 so as to cover a mesh filter support 7. Blood enters through the blood inlet 4, passes through the mesh filter 2, and exits through the blood outlet 5.
【0003】このメッシュフィルター2は、人工臓器透
析基準によると、「血液回路には、薬液注入、採血部を
備え、静脈側回路には、エアートラップ及び濾網を備え
ていなければならない。網の目の大きさは、210μm
(70メッシュ)より細かなもの又はこれと同等の性能
を有する構造のものでなければならない。ろ過網(フィ
ルター)は、異物、血液の凝固物のような粒子、気泡な
どを除去するため、普通ナイロン(商標名)、ポリエス
テルでつくられる。糸径は、均一で表面がなめらかであ
ることが望ましく、また糸をよったマルチフィラメント
よりも1本の糸からなるモノフィラメントの方が血液適
合性において好ましい。」との規定があり、この規定に
基づいて製造されている。According to the standard for dialysis of artificial organs, the mesh filter 2 is described as follows: "The blood circuit must be provided with a drug solution injection and blood collection unit, and the venous circuit must be provided with an air trap and a filter net. Eye size is 210μm
(70 mesh) It must be finer or of a structure having performance equivalent to this. Filtration nets (filters) are usually made of nylon (trade name) or polyester to remove foreign matter, particles such as blood clots, and air bubbles. It is desirable that the yarn diameter is uniform and the surface is smooth, and a monofilament consisting of one yarn is more preferable than a multifilament formed by yarn in terms of blood compatibility. The product is manufactured based on this rule.
【0004】生体適合材料の一種であるメッシュフィル
ター2で血液中の異物、血液の凝固物のような粒子、気
泡などを除去する。この生体適合材料は、一般には非イ
オン性の材料からなり、このような材料表面に対するタ
ンパク質の吸着に関して以下の如き報告がある。「血液
中の血漿に最も高い濃度で含まれている血清アルブミン
が、まず最初に材料表面に吸着するが、脱着も起こると
ともに微量しか存在しないタンパク質も遅れて吸着す
る。その結果、百種以上も存在するタンパク質の中か
ら、その分子量、形状、電荷、表面の親水性・疎水性、
変性のしやすさなどに応じてある特定のタンパク質群が
吸着平衡に達する。解離基を高濃度にもつ表面へ図2に
示されるようにクーロン力で吸着したタンパク質はある
程度の変性を受けるであろうが、非イオン性の材料表面
にファンデルワールス力などで吸着したタンパク質の高
次構造の変化はまだ詳しくは研究されていない〔「生体
適合材料」(日本規格協会出版)参照〕。」(図2中、
8は生体適合材料、9は生体成分である。)[0006] A mesh filter 2 which is a kind of biocompatible material removes foreign substances in blood, particles such as blood coagulation, air bubbles, and the like. This biocompatible material is generally composed of a nonionic material, and the following reports have been made regarding the adsorption of proteins to the surface of such a material. "The highest concentration of serum albumin in blood plasma first adsorbs to the surface of the material, but it also desorbs and delays the adsorption of small amounts of proteins. Among the existing proteins, their molecular weight, shape, charge, surface hydrophilicity / hydrophobicity,
A specific protein group reaches adsorption equilibrium depending on the easiness of denaturation. As shown in FIG. 2, a protein adsorbed to a surface having a high concentration of dissociating groups by Coulomb force will undergo some degree of denaturation, but a protein adsorbed to a nonionic material surface by van der Waals force or the like will be affected. Changes in higher-order structure have not been studied in detail yet (see "Biocompatible Materials" (published by the Japan Standards Association)). (In FIG. 2,
8 is a biocompatible material, and 9 is a biological component. )
【0005】近年、患者の副作用を考慮し、ヘパリン、
フサン、フラグミン等の抗凝固剤の使用量を減らす傾向
があるが、一方、これに対してメッシュフィルターを親
水性高分子を用いてコーティングすることにより抗血栓
性を有するメッシュフィルターを製造する方法も考えら
れる。In recent years, heparin,
There is a tendency to reduce the amount of anticoagulants such as Fusan and Fragmin, but on the other hand, there is also a method of manufacturing a mesh filter having antithrombotic properties by coating the mesh filter with a hydrophilic polymer. Conceivable.
【0006】[0006]
【発明が解決しようとする課題】しかしながら、透析を
繰り返すごとに除水が行われ、ヘマトクリット値が変動
し、血液粘性が上昇する。そこで体外循環中において、
血液凝固時間を一定の範囲内にコントロールするために
薬剤の投与が行われる。このような中で、特に、血小板
凝集抑制薬及び経口抗凝固薬等が必要な患者、すなわち
過凝血性患者や局所ヘパリン化で硫酸プロタミン併用時
(Regional Heparinization)
の患者では、血液回路内及びダイアライザー内に血液凝
固(血液回路内では、ほとんどチャンバー本体内のメッ
シュフィルター部と溶着部周辺に血液凝固が起こる。)
を起こし血栓の生じる傾向にあり、したがって透析中に
血液回路の交換を行わなければならず、患者に対する負
担や病院側の労力の負担も大きいという問題がある。更
に、メッシュフィルターを親水性高分子を用いてコーテ
ィングする方法では、コスト面や手間がかかる等のデメ
リットがあり好ましくない。However, every time dialysis is repeated, water is removed, the hematocrit value fluctuates, and the blood viscosity increases. So during extracorporeal circulation,
Drugs are administered to control the blood clotting time within a certain range. Under these circumstances, in particular, patients requiring a platelet aggregation inhibitor and an oral anticoagulant, such as hypercoagulable patients and local heparinization when combined with protamine sulfate (Regional Heparinization)
Blood coagulation in the blood circuit and in the dialyzer (in the blood circuit, blood coagulation occurs mostly around the mesh filter portion and the welded portion in the chamber body).
The blood circuit must be replaced during dialysis, which causes a problem that the burden on the patient and the burden on the hospital are large. Further, the method of coating the mesh filter with a hydrophilic polymer is not preferable because it has disadvantages such as cost and labor.
【0007】そこで、本発明者等は、前述の血液回路中
にあるチャンバー本体内のメッシュフィルター部におけ
る血栓の付着を直接防止することによって、血液回路の
交換を行う必要をなくし、しいては患者に対する負担や
病院側の労力の負担を軽減するべく種々検討した結果、
特定の材料からなるメッシュフィルターを放電処理する
ことによって血栓の付着のないメッシュフィルターを得
ることができること並びに経済的に安価であり、手間が
かからなく簡単かつ容易に量産し得ることを見出し、こ
こに本発明を完成するに至った。したがって、本発明が
解決しようとする第1の課題は、血液循環回路で体液処
理中の血栓の発生を極力抑制し得ると共にメッシュフィ
ルターに対する血漿蛋白の付着を防止し得る体液処理回
路用抗血栓メッシュフィルターを提供することにある。
また本発明が解決しようとする第2の課題は、経済的に
安価であり、手間がかからなく簡単かつ容易に量産し得
る体液処理回路用抗血栓メッシュフィルターの処理方法
を提供することにある。Accordingly, the present inventors have eliminated the necessity of exchanging a blood circuit by directly preventing the attachment of a thrombus to the mesh filter portion in the chamber main body in the above-mentioned blood circuit, thereby eliminating the need for replacing the blood circuit. As a result of various studies to reduce the burden on hospitals and the burden on hospitals,
It has been found that by subjecting a mesh filter made of a specific material to discharge treatment, it is possible to obtain a mesh filter free of thrombus adhesion, and that it is economically inexpensive, can be easily and easily mass-produced without labor. Thus, the present invention has been completed. Accordingly, a first problem to be solved by the present invention is to provide an anti-thrombosis mesh for a body fluid treatment circuit capable of minimizing the generation of thrombus during body fluid treatment in the blood circulation circuit and preventing the attachment of plasma proteins to the mesh filter. It is to provide a filter.
A second problem to be solved by the present invention is to provide a method of treating an antithrombotic mesh filter for a body fluid treatment circuit which is economically inexpensive, can be easily and easily mass-produced without labor. .
【0008】[0008]
【課題を解決するための手段】本発明の前記の課題は、
以下の各発明によってそれぞれ達成される。The above object of the present invention is to provide:
The invention is achieved by the following inventions.
【0009】(1)ポリアミド又はポリエステルから選
択された生体適合材料から得られた体液処理用メッシュ
フィルターをコロナ放電処理して抗血栓性を付与したこ
とを特徴とする体液処理回路用抗血栓メッシュフィルタ
ー。 (2)ポリエステルがポリエチレンテレフタレートであ
ることを特徴とする前記第1項に記載の体液処理回路用
抗血栓メッシュフィルター。 (3)体液処理用メッシュフィルターの表面が親水性を
有することを特徴とする前記第1項又は第2項に記載の
体液処理回路用抗血栓メッシュフィルター。 (4)ポリアミド又はポリエステルから選択された生体
適合材料から得られた体液処理用メッシュフィルターを
処理強度が3W/m2 /min〜150W/m2/mi
nのコロナ放電を用いて、メッシュフィルターの両面を
処理することを特徴とする体液処理回路用抗血栓メッシ
ュフィルターの製造方法。 (5)常温下で大気圧中で行う、処理電力が600W〜
1200W、処理強度が100W/m2 /min〜15
0W/m2 /min及び周波数10〜20KHZのコロ
ナ放電処理を用いて、メッシュフィルターの両面を処理
することを特徴とする前記第4項に記載の体液処理回路
用抗血栓メッシュフィルターの製造方法。[0009] (1) antithrombotic body fluid processing circuit, characterized in that the body fluid treatment mesh filters obtained from polyamide or polyester Le whether we selected biocompatible materials impart anti-thrombotic and corona discharge treatment Mesh filter. (2) The antithrombotic mesh filter for a body fluid treatment circuit according to the above (1), wherein the polyester is polyethylene terephthalate. (3) The antithrombotic mesh filter for a humor treatment circuit according to the above (1) or (2), wherein the surface of the humor treatment mesh filter has a hydrophilic property. (4) a living body selected from polyamide or polyester
Mesh filter for body fluid treatment obtained from compatible materials
Processing strength is 3W / m 2 / min~150W / m 2 / mi
with n corona discharge, it features and to that body fluid antithrombotic Messi for processing circuit <br/> Interview filter manufacturing method of treating the surfaces of the mesh filter. (5) The processing power is 600 W to be performed at normal temperature and atmospheric pressure.
1200 W, treatment intensity 100 W / m 2 / min ~ 15
5. The method for producing an antithrombotic mesh filter for a body fluid treatment circuit according to claim 4, wherein both sides of the mesh filter are treated using corona discharge treatment at 0 W / m 2 / min and a frequency of 10 to 20 KHZ.
【0010】[0010]
【発明の実施の形態】以下に本発明を更に詳しく説明す
ると、本発明の体液処理回路用抗血栓メッシュフィルタ
ーは、ポリアミド又はポリエステルから選択された生体
適合材料から得られた体液処理用メッシュフィルターを
コロナ放電処理して抗血栓性を付与したことを特徴とす
るもので、これにより前記各材料には充分なコロナ放電
処理が施され、血栓乃至血漿蛋白等の付着を抑制するこ
とができる。更に前記の生体適合材料のうち、ポリ酢酸
ビニル、ポリウレタン、ポリアクリロニトリル、エチレ
ン−ビニルアルコール共重合体、セルロースアセテー
ト、再生セルロースあるいはシリコーンゴムは、人工腎
臓にも使用され、優れた抗血栓性を発揮する点で好まし
い。When DETAILED DESCRIPTION OF THE INVENTION The present invention will be explained in further detail below, the body fluid treatment circuit antithrombotic mesh filter for the present invention, a body fluid treatment mesh obtained from polyamide or polyester Le whether we selected biomaterials The filter is provided with antithrombotic properties by corona discharge treatment, whereby each of the above materials is subjected to a sufficient corona discharge treatment to suppress adhesion of thrombus or plasma proteins. . Further, among the above biocompatible materials, polyvinyl acetate, polyurethane, polyacrylonitrile, ethylene-vinyl alcohol copolymer, cellulose acetate, regenerated cellulose or silicone rubber are also used in artificial kidneys and exhibit excellent antithrombotic properties. Is preferred.
【0011】本発明に用いられる生体適合材料は、ポリ
アミド又はポリエステルから選択される。これらの材料
を1本の糸からなるフィラメントに形成し、網を形成す
るのが好ましい。本発明では、この網の状態でコロナ放
電処理し、ついでフィルターに形成してもよく、また網
をフィルターに形成してから、コロナ放電処理を行って
もよい。好ましくは後者である。コロナ放電処理として
は、基材を支えるローラーを電極とし、これに対向した
電極を設け、これらの電極間に高電圧を加えることによ
りコロナ放電を起こすと共に基材を移動しながら基材前
面にコロナ放電処理を施す方法が通常用いられる。この
コロナ放電処理の結果、基材表面には酸化やイオン化が
起こり活性化されると考えられている。The biocompatible material used in the present invention is selected from polyamide or polyester. It is preferable to form these materials into a filament consisting of one thread to form a net. In the present invention, a corona discharge treatment may be performed in the state of the net, and then the filter may be formed. Alternatively, a corona discharge treatment may be performed after the net is formed in the filter. Preferably the latter. In the corona discharge treatment, a roller that supports the substrate is used as an electrode, electrodes facing the roller are provided, and a corona discharge is generated by applying a high voltage between these electrodes, and the corona is moved to the front of the substrate while moving the substrate. A method of performing a discharge treatment is usually used. It is considered that as a result of the corona discharge treatment, oxidation and ionization occur on the surface of the base material to be activated.
【0012】[0012]
【0013】本発明のコロナ放電処理に必要な電力は、
通常、600W〜1200Wであり、材料を処理するに
必要な処理強度は、3W/m2 /min〜150W/m
2 /minである。常温下で大気圧中で行うコロナ放電
の場合には、材料によって異なるが、3W/m2 /mi
n〜150W/m2 /minであり、例えばポリエチレ
ンの場合は、3W/m2 /min〜15W/m2 /mi
nであり、ポリエステルの場合には、30W/m2 /m
in〜60W/m2 /minである。本発明では、この
ようなコロナ放電処理によりメッシュフィルターの表面
の水に対する接触角を60度以下にすることができ、好
ましくは55度〜40度である。更に好ましくは50度
〜40度であり、これらのコロナ放電処理で40度以下
のものが得られれば、40度以下でもよい。The electric power required for the corona discharge treatment of the present invention is as follows:
Usually, it is 600 W to 1200 W, and the processing strength required for processing the material is 3 W / m 2 / min to 150 W / m.
2 / min. If the line Uco corona discharge at atmospheric pressure at room temperature varies depending on the material, 3W / m 2 / mi
n to 150 W / m 2 / min, for example, in the case of polyethylene, 3 W / m 2 / min to 15 W / m 2 / mi
n and 30 W / m 2 / m in the case of polyester.
in to 60 W / m 2 / min. In the present invention, the contact angle of water on the surface of the mesh filter can be reduced to 60 degrees or less, preferably 55 degrees to 40 degrees by such corona discharge treatment. The angle is more preferably 50 to 40 degrees, and may be 40 degrees or less as long as a value of 40 degrees or less can be obtained by these corona discharge treatments.
【0014】本発明に用いられる、常温下で大気圧中で
行うコロナ放電処理は、処理条件が処理電力600W〜
1200W(処理強度100〜150W/m2 /mi
n)、周波数10〜20KHZ、電極との距離0.2m
m〜1.5mmとして常温下で両面に加工処理すること
により行われる。この結果その表面に空気中の酸素が反
応して水酸基やカルボキシル基等が生成され、親水性と
なり、したがってこのメッシュフィルターは抗血栓性が
得られる。[0014] used in the present invention, <br/> row Uco corona discharge treatment at atmospheric pressure at room temperature, the processing conditions processing power 600W~
1200 W (processing intensity 100 to 150 W / m 2 / mi
n), frequency 10-20 KHZ, distance 0.2 m from electrode
It is performed by processing both sides at room temperature with a diameter of m to 1.5 mm. As a result, oxygen in the air reacts with the surface to generate hydroxyl groups, carboxyl groups, and the like, and the surface becomes hydrophilic. Therefore, the mesh filter has antithrombotic properties.
【0015】[0015]
【0016】本発明の体液処理回路用メッシュフィルタ
ーの放電処理方法は、コロナ放電を施すことを特徴とす
るものであり、具体的には大気中で電極間に発生したコ
ロナ放電による処理をメッシュフィルターの両面に施す
ことを特徴とする体液処理回路用メッシュフィルターの
コロナ放電処理方法であり、常温下で大気圧中で処理条
件が処理電力600W〜1200W(処理強度100〜
150W/m2 /min)、周波数10〜20KHZ、
電極との距離0.2mm〜1.5mmとして両面に加工
処理することを特徴とする体液処理回路用メッシュフィ
ルターのコロナ放電処理方法が好ましい。特にポリエチ
レンテレフタレートの場合には表面の有機物の洗浄効果
が得られるばかりでなく耐久性に優れたものが得られ
る。The discharge treatment method of the mesh filter for a body fluid treatment circuit according to the present invention is characterized in that a corona discharge is performed. Specifically, the treatment by the corona discharge generated between the electrodes in the atmosphere is performed by a mesh filter. of a body fluid treatment circuit for mesh filter corona discharge treatment method characterized by applying to both sides, the process conditions in the atmospheric pressure processing power 600W~1200W (treatment intensity 100 under normal temperature
150 W / m 2 / min), frequency 10-20 KHZ,
A corona discharge treatment method for a mesh filter for a bodily fluid treatment circuit, characterized in that both surfaces are processed at a distance of 0.2 mm to 1.5 mm from the electrode. In particular, in the case of polyethylene terephthalate, not only an effect of cleaning organic substances on the surface can be obtained, but also excellent durability can be obtained.
【0017】(作用)本発明において、体液処理回路を
循環する体液は、該回路中のメッシュフィルターにより
体液中の微少異物や血栓凝固物が取り除かれるが、該メ
ッシュフィルターには、コロナ放電処理が施されている
ことにより、その表面が親水性を有するので、体液が抵
抗なくメッシュフィルターを通過し血栓ができにくい。
更に負電位を有するので、血栓の形成や血漿蛋白の付着
が起こりにくい。また本発明の体液処理回路用メッシュ
フィルターの放電処理方法により、前述の材料から選ば
れた生体適合材料の表面に存在する有機物が洗浄されて
除去される。特にポリエチレンテレフタレートを繊維に
した場合、その表面が毛羽立たないばかりでなく耐久性
に優れたものが得られる。(Operation) In the present invention, the bodily fluid circulating in the bodily fluid treatment circuit removes minute foreign substances and thrombus clots in the bodily fluid by a mesh filter in the circuit, and the mesh filter is subjected to corona discharge treatment. By being applied, the surface has hydrophilicity, so that the body fluid does not easily pass through the mesh filter and is hardly clotted.
Furthermore, since it has a negative potential, formation of a thrombus and adhesion of plasma proteins hardly occur. Further, according to the discharge treatment method of the mesh filter for a body fluid treatment circuit of the present invention, the organic substances present on the surface of the biocompatible material selected from the aforementioned materials are washed and removed. In particular, when polyethylene terephthalate is used as a fiber, not only the surface is not fluffy but also excellent durability can be obtained.
【0018】[0018]
【実施例】以下、本発明を更に実施例を用いて詳しく説
明するが、これは本発明の一例であって、本発明はこれ
に限定されるものではない。EXAMPLES Hereinafter, the present invention will be described in more detail with reference to Examples, but these are only examples of the present invention, and the present invention is not limited thereto.
【0019】参考例1 〔接触角の測定〕ポリエステル
フィルム(ルミラー、東レ株式会社製)及びポリプロピ
レンフィルム(IPP、大倉工業株式会社製)の2種類
のフィルムについて、それぞれ処理前のものとコロナ放
電処理を施したものを用意した。ここでコロナ放電処理
条件は、処理電力950W、処理強力115W/m2 /
min、周波数10KHz、電極間の距離0.1〜0.
2mmで行った。コロナ放電処理前及び処理後の2種類
のフィルムについて、接触角を10回測定し、その平均
を表1に示した。ここで接触角の測定は、JIS L1
092−1986繊維製品の防水性試験方法に準じて行
った(室温20℃、溶液:イオン交換水、液温17
℃)。Reference Example 1 [Measurement of Contact Angle] Two types of films, a polyester film (Lumirror, manufactured by Toray Industries, Inc.) and a polypropylene film (IPP, manufactured by Okura Industries Co., Ltd.), before and after corona discharge treatment, respectively. Prepared. Here, the corona discharge treatment conditions were as follows: treatment power 950 W, treatment intensity 115 W / m 2 /
min, frequency 10 KHz, distance between electrodes 0.1-0.
Performed at 2 mm. The contact angles of the two types of films before and after the corona discharge treatment were measured 10 times, and the average is shown in Table 1. Here, the measurement of the contact angle is based on JIS L1
092-1986 Performed according to the waterproof test method for textiles (room temperature 20 ° C., solution: ion-exchanged water, liquid temperature 17).
° C).
【0020】[0020]
【表1】 [Table 1]
【0021】〔ぬれ性の測定〕コロナ放電処理した2種
類のポリエステルメッシュのぬれ性をJIS K676
8−1977のポリエチレン及びポリプロピレンフィル
ムのぬれ試験方法に準じて行った。ここでコロナ放電処
理条件は、処理電力1100W、処理強力100W/m
2 /min、周波数12KHz、電極間の距離0.1〜
0.2mmで行った。コロナ放電処理した2種類のフィ
ルム(品番:ポリエステルのTNO70SS及びTO8
0SS)について、表面張力を測定し、表2に示した。
なお、試験は試薬をメッシュ上に10滴たらし、浸透し
た個数を数えることにより行う。[Measurement of wettability] The wettability of two types of polyester mesh subjected to corona discharge treatment was measured according to JIS K676.
It carried out according to the wetting test method of the polyethylene and polypropylene film of 8-1977. Here, the corona discharge treatment conditions were a treatment power of 1100 W and a treatment intensity of 100 W / m.
2 / min, frequency 12 KHz, distance between electrodes 0.1 to
Performed at 0.2 mm. Two types of corona-discharge treated films (Product No .: polyester TNO70SS and TO8
0SS), the surface tension was measured and is shown in Table 2.
The test is performed by dropping 10 drops of the reagent on the mesh and counting the number of permeated reagents.
【0022】[0022]
【表2】 [Table 2]
【0023】実施例1 本発明の製品であるメッシュク
ロスの条件のポリエチレンテレフタレート製70メッシ
ュフィルター(線径55±6μm、オープニング310
±30μm)をコロナ放電処理として、処理電力110
0W、処理強力100W/m2/min、周波数12K
Hz、電極間の距離0.1〜0.2mmで施した製品と
従来品としては、無処理のポリエチレンテレフタレート
製70メッシュフィルター(線径72±7μm、オープ
ニング292±30μm)を用いて、人工透析血液回路
の血栓試験を行った。人工透析血液回路用チャンバー内
における凝血、残血発生率及びその状況を表3に示す。EXAMPLE 1 A 70-mesh filter made of polyethylene terephthalate (wire diameter 55 ± 6 μm, opening 310) under the condition of a mesh cloth which is a product of the present invention.
± 30 μm) as the corona discharge treatment,
0W, processing power 100W / m 2 / min, frequency 12K
Hz and a distance between the electrodes of 0.1 to 0.2 mm, and the conventional product was subjected to artificial dialysis using an untreated polyethylene terephthalate 70 mesh filter (wire diameter 72 ± 7 μm, opening 292 ± 30 μm). A blood circuit thrombus test was performed. Table 3 shows the rate of occurrence of coagulation and residual blood in the chamber for the artificial dialysis blood circuit and the situation.
【0024】〔ドリップチャンバー内の凝血・残血の状
況〕 −−:凝血・残血が全くない。 − :凝血・残血が殆どない。 + :凝血・残血がある。 ++:凝血・残血がかなりある。 なお、ヘマトクリット値の正常値(毛細管法)は、男:
39〜52%、女:35〜48%である。[Status of Clotting / Blood in Drip Chamber] ---: There is no clotting / bleeding. -: Almost no clot or residual blood. +: There is blood clot or residual blood. ++: There is considerable coagulation and residual blood. The normal value of the hematocrit value (capillary method) is:
39-52%, female: 35-48%.
【0025】[0025]
【表3】 [Table 3]
【0026】[0026]
【0027】実施例2 実施例1のコロナ放電処理を施
した製品と従来品について、統計学的手法(χ2 検定)
で検定した結果を表4に示す。なお、統計学的手法(χ
2 検定)は、「統計的方法(日本規格協会出版):分割
表に関する検定」に記載されている。[0027] The product and conventional products was subjected to corona discharge treatment in Example 1, statistical methods (chi 2 test)
Table 4 shows the test results. In addition, statistical methods (χ
2 ) are described in “Statistical Method (Published by the Japan Standards Association): Test on Contingency Table”.
【0028】[0028]
【表4】 表4から明らかなように、本発明の製品は、χ0 2=1
8.4であり、分割表による検定でも従来品のχ2
(1、0.05)=3.84(危険率5%)よりその値
が大きいので、本発明の製品は、効果のあることがわか
る。したがって、本発明の製品は、残血が殆どなく、抗
血栓メッシュフィルターとして優れている。 [Table 4] As is evident from Table 4, the product of the present invention has χ 0 2 = 1.
8.4 and is, of conventional even in the assay by the contingency table goods χ 2
Since the value is larger than (1, 0.05) = 3.84 (hazard rate 5%), it is understood that the product of the present invention is effective. Therefore, the product of the present invention has little residual blood and is excellent as an antithrombotic mesh filter .
【0029】[0029]
【0030】[0030]
【発明の効果】本発明の如く放電処理を施したメッシュ
フィルターは、優れた抗血栓性を有し、血液循環回路で
体液処理中の血栓の発生を極力抑制し得ると共にメッシ
ュフィルターに対する血漿やたんぱく質の付着を防止し
得るという優れた効果を奏するものである。また本発明
の放電処理方法によれば、経済的に安価であり、手間が
かからなく簡単かつ容易に量産し得るという優れた効果
を奏するものである。EFFECTS OF THE INVENTION The mesh filter subjected to the discharge treatment as in the present invention has excellent antithrombotic properties, can minimize the generation of thrombus during the treatment of body fluids in the blood circulation circuit, and has the plasma and protein against the mesh filter. This has an excellent effect of preventing the adhesion of water. Further, according to the discharge treatment method of the present invention, there is an excellent effect that it is economically inexpensive, can be easily and easily mass-produced without any trouble.
【図1】従来のメッシュフィルターが設置されたチャン
バーを示す略図である。FIG. 1 is a schematic view showing a chamber in which a conventional mesh filter is installed.
【図2】生体適合材料と生体成分との電荷関係を示す略
断面図である。FIG. 2 is a schematic cross-sectional view showing a charge relationship between a biocompatible material and a biological component.
1 ドリップチャンバー本体 2 メッシュフィルター 3 キャップ 4 血液導入口 5 血液導出口 6 圧力モニター用ラインチューブ 7 メッシュフィルター支持体 8 生体適合材料 9 生体成分(例えばタンパク質等) DESCRIPTION OF SYMBOLS 1 Drip chamber main body 2 Mesh filter 3 Cap 4 Blood inlet 5 Blood outlet 6 Pressure monitor line tube 7 Mesh filter support 8 Biocompatible material 9 Biological component (for example, protein etc.)
───────────────────────────────────────────────────── フロントページの続き (72)発明者 杉山 喜一 東京都日野市豊田2丁目50番地の3 エ ヌ・ビー・シー工業株式会社内 (72)発明者 川端下 栄治 東京都日野市豊田2丁目50番地の3 エ ヌ・ビー・シー工業株式会社内 (56)参考文献 特開 平4−200475(JP,A) 特開 平7−204263(JP,A) 特開 平3−218771(JP,A) 特開 平6−304243(JP,A) 国際公開94/17904(WO,A1) (58)調査した分野(Int.Cl.7,DB名) A61L 33/00 A61M 1/34 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Kiichi Sugiyama 2-350 Toyota, Hino-shi, Tokyo Inside NBC Industry Co., Ltd. (72) Inventor Eiji Kawabata 2-chome Toyota, Hino-shi, Tokyo Reference No. 50 at 3NBC Industrial Co., Ltd. (56) References JP-A-4-200475 (JP, A) JP-A-7-204263 (JP, A) JP-A-3-218771 (JP, A A) JP-A-6-304243 (JP, A) WO 94/17904 (WO, A1) (58) Fields investigated (Int. Cl. 7 , DB name) A61L 33/00 A61M 1/34
Claims (5)
た生体適合材料から得られた体液処理用メッシュフィル
ターをコロナ放電処理して抗血栓性を付与したことを特
徴とする体液処理回路用抗血栓メッシュフィルター。1. A antithrombotic mesh body fluid processing circuit, characterized in that the body fluid treatment mesh filters obtained from polyamide or polyester Le whether we selected biocompatible materials impart anti-thrombotic and corona discharge treatment filter.
トであることを特徴とする請求項1に記載の体液処理回
路用抗血栓メッシュフィルター。2. The antithrombotic mesh filter for a body fluid treatment circuit according to claim 1, wherein the polyester is polyethylene terephthalate.
水性を有することを特徴とする請求項1又は請求項2に
記載の体液処理回路用抗血栓メッシュフィルター。3. The antithrombotic mesh filter for a body fluid treatment circuit according to claim 1, wherein the surface of the mesh filter for treating body fluid has hydrophilicity.
た生体適合材料から得られた体液処理用メッシュフィル
ターを処理強度が3W/m2 /min〜150W/m2
/minのコロナ放電を用いて、メッシュフィルターの
両面を処理することを特徴とする体液処理回路用抗血栓
メッシュフィルターの製造方法。4. A material selected from polyamide or polyester.
Mesh for body fluid treatment obtained from biocompatible materials
Ter the processing strength of 3W / m 2 / min~150W / m 2
/ Using corona discharge min, features and to that body fluid processing circuit antithrombotic <br/> mesh filter manufacturing method for treating the surfaces of the mesh filter.
0W〜1200W、処理強度が100W/m2 /min
〜150W/m2 /min及び周波数10〜20KHZ
のコロナ放電処理を用いて、メッシュフィルターの両面
を処理することを特徴とする請求項4に記載の体液処理
回路用抗血栓メッシュフィルターの製造方法。5. The process performed at normal temperature and atmospheric pressure, wherein the processing power is 60
0W~1200W, processing strength is 100W / m 2 / min
~150W / m 2 / min and a frequency 10~20KHZ
The method for producing an antithrombotic mesh filter for a body fluid treatment circuit according to claim 4 , wherein both surfaces of the mesh filter are treated by using the corona discharge treatment of (1) .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09261696A JP3350722B2 (en) | 1996-03-29 | 1996-04-15 | Antithrombotic mesh filter for body fluid treatment circuit and method of manufacturing the same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8-76143 | 1996-03-29 | ||
| JP7614396 | 1996-03-29 | ||
| JP09261696A JP3350722B2 (en) | 1996-03-29 | 1996-04-15 | Antithrombotic mesh filter for body fluid treatment circuit and method of manufacturing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09313595A JPH09313595A (en) | 1997-12-09 |
| JP3350722B2 true JP3350722B2 (en) | 2002-11-25 |
Family
ID=26417294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09261696A Expired - Lifetime JP3350722B2 (en) | 1996-03-29 | 1996-04-15 | Antithrombotic mesh filter for body fluid treatment circuit and method of manufacturing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3350722B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2518100B1 (en) * | 2009-12-24 | 2015-02-18 | Toray Industries, Inc. | Hydrophilic polymer compound having anticoagulation effect |
| DE102011108777A1 (en) | 2011-07-29 | 2013-01-31 | Fresenius Medical Care Deutschland Gmbh | Method for removing blood from an extracorporeal blood circulation and devices |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017904A1 (en) | 1993-02-10 | 1994-08-18 | Akzo Nobel N.V. | Modified membrane for medical purposes |
-
1996
- 1996-04-15 JP JP09261696A patent/JP3350722B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017904A1 (en) | 1993-02-10 | 1994-08-18 | Akzo Nobel N.V. | Modified membrane for medical purposes |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH09313595A (en) | 1997-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4059543B2 (en) | Medical device for extracorporeal treatment of blood or plasma and method for manufacturing the device | |
| US5151192A (en) | Method for removing heparin from blood or plasma | |
| US9878085B2 (en) | Method for the elimination of leukocytes from blood | |
| EP2042230B1 (en) | Hydrophilic membranes with a non-ionic surfactant | |
| JP4234345B2 (en) | Non-aggregating semipermeable membrane and process for producing the same | |
| JP2017513636A (en) | Method for removing bacteria from blood using high flow rate | |
| TW201233434A (en) | Medical material and hollow fiber membrane module | |
| JP2022534191A (en) | Methods for modulating endothelial glycocalyx | |
| JP4579916B2 (en) | Membrane surface treatment and related products | |
| US6454998B1 (en) | Blood circulation apparatus coupling device which improves biocompatibility of inner surfaces with treated blood | |
| CN114653222A (en) | Low-nonspecific adsorption virus removal filter membrane and preparation method thereof | |
| JP6291970B2 (en) | Protein adsorbing material, method for producing the same, blood purifier | |
| JP3350722B2 (en) | Antithrombotic mesh filter for body fluid treatment circuit and method of manufacturing the same | |
| JPWO1999010025A1 (en) | Leukocyte removal material and method for producing hydrophilized polyolefin | |
| US20050009001A1 (en) | Device for removing bacterial lipopolysaccharides and/or lipoteichoic acids from protein-containing fluids and its use for the treatment of sepsis | |
| JP4683402B2 (en) | Hollow fiber membrane for blood purification, method for producing the same, and blood purifier | |
| US5525279A (en) | Method of forming a granulocyte adsorbing carrier and granulocyte remover | |
| JP4381073B2 (en) | Blood purification membrane with excellent blood compatibility | |
| JP2005065711A (en) | Adsorbing material and method for producing adsorbing material | |
| JP4148310B2 (en) | Leukocyte selective removal filter | |
| JPS61226056A (en) | Blood filter | |
| GB1577714A (en) | Blood purification module | |
| JP4304611B2 (en) | Permselective hollow fiber membrane with excellent blood compatibility | |
| JP2017113181A (en) | Blood circulation column and centrifuge | |
| JP2006271459A (en) | Method for evaluating body fluid treatment column material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080920 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080920 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080920 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100920 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100920 Year of fee payment: 8 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100920 Year of fee payment: 8 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100920 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110920 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120920 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120920 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130920 Year of fee payment: 11 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |